Pathophysiological markers of metabolic disease included the level of visceral and subcutaneous adiposity, adipocyte diameter, markers of chronic systemic inflammation (hsCRP), hepatic lipotoxicity (ALT, AST, GGT, hepatic lipids), atherogenic risk and whole-body insulin sensitivity (M-value). This evidence concerns the gene GPT and metabolic disease.